Table 5.
Levels of in vitro resistance for HIV-1 INSTI mutated viruses with elvitegravir resistance pathways
| Genotype | RAL | EVG | DTG | CTG | BIC |
|---|---|---|---|---|---|
| T66 | |||||
| T66A | − | + | − | − | NA |
| T66A/S153F | − | ++ | NA | NA | NA |
| T66I | − | + | − | − | NA |
| T66I/L74M | + | ++ | − | − | NA |
| T66I/E92Q | ++ | +++ | − | − | NA |
| T66I/F121Y | + | ++ | NA | NA | NA |
| T66I/S153Y | − | +++ | NA | NA | NA |
| T66I/E157Q | − | ++ | − | NA | − |
| T66I/Q146P | NA | +++ | NA | NA | NA |
| T66I/Q146P/S147G | NA | +++ | NA | NA | NA |
| T66I/Q95K/Q146P/S147G | NA | +++ | NA | NA | NA |
| T66I/Q95K/E138K/Q146P/S147G | NA | +++ | NA | NA | NA |
| T66I/T97A/E157Q | − | ++ | − | NA | − |
| T66I/R263K | − | ++ | − | NA | NA |
| T66I/E138K/R263K | + | +++ | − | NA | NA |
| T66K | + | +++ | − | − | NA |
| T66K/L74M | ++ | +++ | + | + | NA |
| E92 | |||||
| E92G | − | + | − | NA | NA |
| E92G/S153F | − | + | NA | NA | NA |
| E92I | − | + | − | − | |
| E92Q | + | ++ | − | − | − |
| V72I/E92Q/E157Q | + | ++ | NA | NA | NA |
| E92Q/S147G | − | + | NA | NA | NA |
| H51Y/E92Q/S147G | NA | +++ | NA | NA | NA |
| H51Y/E92Q/S147G/E157Q | NA | +++ | NA | NA | NA |
| E92Q/E157Q | ++ | ++ | − | NA | − |
| E92Q/R263K | + | +++ | − | NA | |
| E92V | − | + | − | − | NA |
Scale: ‘−’ no fold-change (FC), ‘+’ low FC, ‘++’ moderate FC, and ‘+++’ high FC from measured WT 50% inhibitory concentration (EC50). NA denotes no value available. Numbers refer to amino acid position in HIV integrase, one letter amino acid code used
References: [14, 16, 28, 29, 31, 32, 36, 40, 43–45, 49–52, 54–69]